BioEcho develops single-spin and 96-well kits for the isolation of DNA from different starting materials. In contrast to common bind-wash-elute procedures, their proprietary EchoLUTION single-step technology avoids the use of inhibitory or harmful process reagents and does not require washing steps. 90% of the disposal costs are saved as well as more than 40% of the pipet tip consumption costs. The inhibitor-free DNA enables lowered time-to-result in enzyme-dependent genomic analyses such as PCR or NGS.

CTO Lars Nieba has taken over as interim CEO at Nordic Nanovectors after Eduardo Bravo’s sudden departure.

The Innovative Medicines Initiative (IMI) has announced a €45m funding for the development of therapeutics and diagnostics to tackle coronavirus outbreaks.

With the financing led by General Atlantic, the British company wants to expand a novel platform and advance its ImmTAX pipeline to the clinic.

She was already serving as interim CEO since Nouscom founder Alfredo Nicosia retired in May 2019. Now, Marina Udier‘s appointment at the Basel-based immuno-oncology company has been made permanent.

High amounts of injected vitamin C may delay the growth of many types of tumours and boost the anticancer power of immune checkpoint therapies, report Italian oncologists.

Roche AG‘s has paid US$30m upfront in a potential US$1.7bn deal to get access to Bicycle Therapeutics plc’s technology platform to target immune checkpoints.

Widespread use of human induced pluripotent stem cell (hiPSC) derived mature cell types is restricted by complex differentiation protocols and inefficient reprogramming methods. By applying a novel gene engineering approach, opti-oxTM, to cellular reprogramming these restrictions have been largely overcome. This proprietary technology enables precise reprogramming and homogeneous differentiation of entire stem cell cultures into any desired cell type.

Researchers at Trinity College in Dublin have demonstrated that resetting brain-specific immune cells improves traumatic brain injury (TBI) recovery.
 

Negotiations of the EU Council on the EU’s seven-year budget have failed, putting R&D funding at risk for significant cuts.